Antibody Production

Antibody Production Market Outlook

The global antibody production market is projected to reach USD 50.7 billion by 2035, at a CAGR of 11.2% during the forecast period of 2025-2035. The increasing incidence of chronic diseases such as cancer and autoimmune disorders is fueling the growth of this market, as the need for effective therapeutic agents rises. Additionally, advancements in biotechnology and increased investments in research and development activities are further driving market expansion. The growing demand for monoclonal antibodies in therapeutic applications is also a significant factor contributing to the market growth. Moreover, the rising number of diagnostic tests utilizing antibodies is spurring demand in this sector, leading to the overall growth in antibody production.

Growth Factor of the Market

The growth of the antibody production market is primarily driven by the escalating prevalence of diseases such as cancer and various infectious diseases, which necessitate the development of innovative therapeutic solutions. Furthermore, the rise in funding for research and development initiatives, particularly in the fields of immunology and oncology, has accelerated advancements in antibody technologies. The growing preference for targeted therapies over traditional treatments is another significant factor propelling this market, as antibodies provide specificity in targeting diseased cells. Additionally, the increasing use of antibodies in diagnostics is enhancing their commercial viability, leading to increased production capacity. Another noteworthy factor is the rising awareness regarding personalized medicine, which often incorporates tailored antibody therapies to optimize patient outcomes.

Key Highlights of the Market

• The market is expected to witness a CAGR of 11.2% from 2025 to 2035.
• Monoclonal antibodies are anticipated to dominate the product type segment due to their extensive application in therapeutics.
• North America is projected to hold the largest market share owing to strong healthcare infrastructure and significant investments in R&D.
• Therapeutics is expected to be the largest application segment as the demand for novel drugs rises.
• Technological advancements in antibody production methods are expected to enhance efficiency and reduce costs.

By Product Type

Monoclonal Antibodies:

Monoclonal antibodies (mAbs) have become a cornerstone in the field of therapeutic interventions and diagnostics. They are engineered to target specific antigens, making them highly effective for treating conditions such as cancer, autoimmune diseases, and infectious diseases. The ability of mAbs to deliver targeted therapies has significantly enhanced treatment outcomes and minimized side effects, which is a major reason for their widespread adoption. The advancements in hybridoma technology and recombinant DNA techniques have further improved the production efficiency and specificity of these antibodies. The market for monoclonal antibodies is expected to grow robustly due to the increasing number of mAb-based drugs approved by regulatory agencies, thus contributing significantly to the overall antibody production market growth.

Polyclonal Antibodies:

Polyclonal antibodies are antibodies that are produced by different B cell lineages within the body. This type of antibody is particularly useful in research and diagnostic applications since they can recognize multiple epitopes on a single antigen. The versatility and relatively lower production costs of polyclonal antibodies compared to monoclonal antibodies make them a popular choice in laboratories and research institutes. Their applications range from immunohistochemistry to ELISA and western blotting, thus emphasizing their importance in various research areas. The increasing demand for polyclonal antibodies in clinical diagnostics and research is driving growth in this segment, particularly for applications that require broad spectrum detection capabilities.

Recombinant Antibodies:

Recombinant antibodies are engineered using recombinant DNA technology, enabling the creation of antibodies with modified characteristics that can enhance their therapeutic efficacy. These antibodies are primarily utilized in therapeutic applications where specificity and reduced immunogenicity are vital. The development of recombinant antibodies is on the rise, fueled by innovations in biotechnology that are yielding more effective and safer products. Furthermore, their ability to be produced in large quantities and tailored to specific therapeutic needs signifies a growing trend in the antibody production market. With ongoing advances in genetic engineering and expression systems, the market for recombinant antibodies is poised for significant growth in the upcoming years.

Murine Antibodies:

Murine antibodies, derived from mice, have been a traditional choice in the antibody production market due to their robustness and effectiveness in research applications. They have been widely used in various diagnostic assays and therapeutic modalities due to their ability to elicit strong immune responses. Despite facing competition from other types of antibodies, murine antibodies continue to be relevant for specific applications, particularly in research settings. The ongoing advancements in production technologies are expected to enhance their yield and specificity, thereby maintaining their position in the market. However, the rising preference for humanized antibodies due to concerns regarding immunogenicity may impact their future market share.

Humanized Antibodies:

Humanized antibodies, which are modified from murine antibodies to reduce the risk of immune response, are gaining traction due to their enhanced safety profile and effectiveness in treating human diseases. These antibodies are particularly valuable in therapeutic applications, as they provide reduced immunogenicity while retaining the ability to target specific antigens. The increasing focus on personalized medicine and targeted therapies has led to a surge in demand for humanized antibodies, particularly in oncology and autoimmune disease treatments. The ongoing research and development efforts directed towards improving the efficacy and specificity of humanized antibodies are expected to significantly drive growth in this segment of the antibody production market.

By Application

Therapeutics:

The therapeutic application segment is the largest contributor to the antibody production market, driven by the increasing prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders. Antibody-based therapies, particularly monoclonal antibodies, have revolutionized the treatment landscape by providing targeted and effective solutions for previously hard-to-treat conditions. Their ability to neutralize specific targets in the body has not only improved patient outcomes but also led to the development of personalized treatment plans. The rapid approval and commercialization of new antibody-based therapeutics are indicative of the market's potential and growing reliance on antibodies in modern medicine. Furthermore, the emergence of biosimilars is anticipated to broaden the accessibility of these therapies, making them more affordable and driving further growth in this segment.

Diagnostics:

In the diagnostics sector, antibodies are widely utilized as key components in various assays, including ELISA, western blotting, and immunohistochemistry. The growing demand for rapid and accurate diagnostic tests, particularly in the wake of global health challenges such as the COVID-19 pandemic, has significantly boosted the antibody production market. Diagnostic antibodies offer unparalleled specificity and sensitivity in detecting various diseases, contributing to early diagnosis and timely treatment. The continuous advancements in diagnostic technologies and the increased adoption of point-of-care testing are further propelling the growth of this segment. As healthcare providers increasingly rely on antibody-based diagnostics to improve patient outcomes, the market for diagnostic antibodies is expected to witness substantial expansion in the coming years.

Research:

The application of antibodies in research is a critical aspect of the antibody production market, as they serve as essential tools for scientists across various fields, including molecular biology, immunology, and biochemistry. Researchers utilize antibodies for a range of applications, including protein interactions, signaling pathways, and cellular mechanisms. The rise in funding for scientific research and the growing emphasis on innovative therapies are driving demand for high-quality research antibodies. Furthermore, advancements in antibody engineering are facilitating the development of next-generation antibodies that offer improved performance in research applications. As the global research community continues to expand, the antibody production market in the research segment is anticipated to grow significantly, contributing to overall market dynamics.

By User

Pharmaceutical & Biotechnology Companies:

Pharmaceutical and biotechnology companies are the primary users of antibodies, primarily for therapeutic development and diagnostics. These companies invest heavily in R&D to create novel antibody-based drugs that can address unmet medical needs. The advancement of personalized medicine has further amplified the demand for custom antibodies that cater to specific patient profiles. The increasing number of clinical trials and the introduction of new antibody therapies into the market underscore the vital role that these companies play in the antibody production landscape. Collaboration with academic institutions and research organizations is also common, as it enhances their ability to innovate and stay competitive in a rapidly evolving market.

Academic & Research Institutes:

Academic and research institutes play a significant role in driving antibody production and utilization, primarily for exploratory research and development. These institutions often require a wide range of antibodies for various applications, including basic research, diagnostic development, and preclinical studies. The funding provided for academic research has been on the rise, leading to increased collaboration with industry to develop innovative antibody-based solutions. Additionally, the growing emphasis on translational research, which bridges laboratory discoveries with clinical application, has positioned academic institutions as key players in the antibody production market. Their involvement in developing new technologies and methodologies for antibody use ensures that the market remains dynamic and responsive to the needs of the healthcare industry.

Contract Research Organizations:

Contract research organizations (CROs) are integral to the antibody production market as they provide essential services for pharmaceutical and biotech companies, enabling them to expedite their research and development processes. CROs offer a range of services including antibody discovery, characterization, and development, which are pivotal in bringing new therapies to market. As the demand for outsourcing increases due to cost constraints and the need for specialized expertise, CROs are positioning themselves as valuable partners in the antibody production ecosystem. The continued growth of the biotechnology sector will likely spur demand for CRO services, further enhancing the antibody production market's potential.

By Technology

Hybridoma Technology:

Hybridoma technology, which was one of the first methods developed for producing monoclonal antibodies, remains a cornerstone in the antibody production market. This technique involves the fusion of B cells with myeloma cells to create hybrid cells that can produce a consistent and unlimited supply of specific antibodies. Despite the emergence of newer technologies, hybridoma technology continues to be favored for its reliability and proven effectiveness. The ability to produce high-affinity antibodies makes this technology particularly valuable for therapeutic and diagnostic applications. However, there is a growing trend toward optimizing and enhancing hybridoma systems to improve yield and reduce production costs, ensuring its relevance in the modern antibody landscape.

Phage Display Technology:

Phage display technology has emerged as a revolutionary method for generating a diverse library of antibodies with tailored specificities. This technology allows researchers to screen vast numbers of antibodies to identify those with the highest affinity for a target antigen, making it highly effective for both therapeutic and diagnostic applications. The ability to rapidly produce and engineer antibodies using phage display has significantly expedited drug development timelines. Additionally, the integration of phage display technology with other molecular techniques has opened new avenues for antibody design and optimization. As the demand for novel therapies increases, the relevance of phage display technology in the antibody production market is expected to grow substantially.

Transgenic Animals Technology:

Transgenic animals technology involves the genetic modification of animals, particularly mice, to produce human-like antibodies in a more efficient manner. This method is gaining traction due to its ability to yield high-affinity human antibodies, which are crucial for therapeutic applications. The use of transgenic animals helps to overcome the limitations associated with traditional hybridoma techniques, particularly in terms of humanization and specificity. As the biotechnology sector advances, the application of transgenic animal technology is anticipated to expand, improving the productivity and efficacy of antibody production. Furthermore, with the increasing focus on reducing animal testing in research, transgenic technology offers a viable alternative that aligns with ethical considerations while maintaining high scientific standards.

Single-Cell Cloning Technology:

Single-cell cloning technology represents a significant advancement in antibody production that allows for the isolation and characterization of individual cells that produce specific antibodies. This technique enhances the ability to discover rare B cells that may produce high-affinity antibodies, thus facilitating the production of novel therapeutics and diagnostics. The precision offered by single-cell cloning is especially advantageous in the context of monoclonal antibody development, as it allows researchers to focus on cells with desirable characteristics. The growing trend toward personalized medicine and targeted therapies is likely to drive the adoption of this technology, making it a key player in the evolving antibody production market.

Recombinant DNA Technology:

Recombinant DNA technology plays an essential role in the development of engineered antibodies by allowing researchers to manipulate genetic material to produce antibodies with enhanced properties. The versatility of recombinant techniques enables the generation of humanized, chimeric, and bispecific antibodies that can target multiple antigens simultaneously. The demand for therapeutic antibodies that offer increased efficacy and fewer side effects is propelling the growth of recombinant DNA technology in the antibody production market. Ongoing advancements in genetic engineering and expression systems are expected to further improve the efficiency and scalability of antibody production, thereby solidifying the importance of recombinant techniques in the industry.

By Region

North America is anticipated to hold the largest market share in the antibody production segment, with a projected market value of approximately USD 18 billion by 2035. This dominance can be attributed to the presence of well-established pharmaceutical companies, a robust healthcare infrastructure, and significant investments in research and development activities. The United States, in particular, has a strong pipeline of antibody-based drugs, driven by favorable regulatory environments and a growing focus on personalized medicine. Furthermore, the increasing incidence of chronic diseases and the rising demand for innovative therapies are contributing to the growth of the antibody production market in this region. The North American market is expected to witness a CAGR of 10.5% during the forecast period, indicating sustained growth potential.

Europe is expected to be the second-largest market for antibody production, with a forecasted market value of around USD 15 billion by 2035. The market in this region is primarily driven by the rising demand for monoclonal antibodies in therapeutic applications and the increasing number of research initiatives in biotechnology. Countries such as Germany, the UK, and France are leading in antibody research and development, supported by government funding and an emphasis on innovation in biosimilars. Additionally, the growing prevalence of diseases such as cancer and autoimmunity is driving the demand for effective antibody-based therapies. The European market is projected to grow at a CAGR of 9.8% between 2025 and 2035, reflecting a robust growth trajectory.

Opportunities

The antibody production market is poised to capitalize on numerous opportunities as advancements in biotechnology evolve. The emergence of biosimilars represents a significant opportunity for growth, as these products provide cost-effective alternatives to expensive monoclonal antibodies. As patents for several blockbuster antibody drugs expire, the market will likely see an influx of biosimilars, driving competition and making high-quality therapies more accessible to patients. Furthermore, the increasing emphasis on personalized medicine opens new avenues for tailored antibody therapies that cater to individual patient profiles, thus enhancing treatment efficacy. The rising prevalence of chronic diseases and the growing need for innovative therapeutic solutions underscore the importance of expanding production capabilities and investing in research to enhance antibody development processes.

Additionally, the growing interest in immunotherapy, particularly in oncology, presents a lucrative opportunity for antibody production. The combination of antibodies with other treatment modalities such as checkpoint inhibitors and CAR-T cell therapies is gaining momentum in cancer treatments, creating a demand for novel antibody products. This trend is expected to drive the development of new therapeutic agents utilizing advanced antibody engineering techniques. Moreover, as healthcare systems globally continue to prioritize early diagnosis and prevention, the demand for diagnostic antibodies is set to rise. This demand will foster investment in R&D and production capabilities, ensuring the antibody production market remains dynamic and responsive to evolving healthcare needs.

Threats

Despite the promising outlook for the antibody production market, several threats could potentially hinder its growth. One of the most significant challenges is the high cost associated with developing and producing monoclonal antibodies, which can limit accessibility for healthcare providers and patients. As the market becomes increasingly competitive, companies may face pressure to lower prices, which could impact profitability and R&D investments. Additionally, there is an ever-present risk of regulatory hurdles that can delay product approvals. Regulatory compliance poses a considerable challenge, especially as the industry navigates complex guidelines concerning safety and efficacy standards.

Another considerable threat comes from the evolving landscape of alternative therapies, such as small-molecule drugs and gene therapies. These alternatives could replace traditional antibody therapies, particularly in certain applications where they may offer comparable or superior efficacy. The rapid pace of innovation in the biotechnology sector means that companies need to stay ahead of the curve or risk losing market share. Furthermore, the global economic climate can also impact funding for research and development activities, posing risks for companies dependent on external financing for their projects. Overall, while the antibody production market presents ample opportunities, it is essential for stakeholders to remain vigilant and adaptable to navigate these potential threats.

Competitor Outlook

• Amgen Inc.
• Roche Holding AG
• AbbVie Inc.
• Johnson & Johnson
• Novartis AG
• Pfizer Inc.
• Merck & Co., Inc.
• Sanofi S.A.
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• GSK (GlaxoSmithKline plc)
• Regeneron Pharmaceuticals, Inc.
• Takeda Pharmaceutical Company Limited
• Biogen Inc.
• Genmab A/S

The competitive landscape of the antibody production market is characterized by the presence of several major players that continually strive to enhance their product offerings and expand their market share. Companies are increasingly engaging in mergers and acquisitions to bolster their R&D capabilities and broaden their product pipelines. The partnerships between biotech firms and academic institutions are also becoming more prevalent, fostering innovation and facilitating the development of cutting-edge antibody technologies. With the rising demand for effective therapeutic solutions, these companies are investing heavily in R&D and concentrating their efforts on developing next-generation antibodies that can address unmet medical needs.

Amgen Inc. is a leader in the biopharmaceutical sector, specializing in monoclonal antibody production. The company has a well-established portfolio of therapeutic antibodies that treat various conditions, including cancer and autoimmune diseases. Roche Holding AG is another key player, known for its innovative approaches to antibody development, particularly in the cancer treatment arena. The company has made significant investments in antibody-drug conjugates, combining the targeting abilities of antibodies with the cytotoxic properties of drugs to enhance treatment effectiveness.

AbbVie Inc. has a prominent position in the antibody production market, particularly with its blockbuster drug, Humira, which is used to treat autoimmune conditions. The company is actively pursuing the development of biosimilars to increase market penetration and lower costs for patients. Johnson & Johnson is also a key player, investing in antibody-based therapies for various therapeutic areas, including oncology and infectious diseases. With ongoing research and development, these companies are expected to remain formidable competitors in the antibody production landscape, continually driving innovation and enhancing treatment options for patients worldwide.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Genmab A/S
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 AbbVie Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Biogen Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Novartis AG
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Pfizer Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Sanofi S.A.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 AstraZeneca PLC
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Roche Holding AG
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Johnson & Johnson
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Merck & Co., Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 GSK (GlaxoSmithKline plc)
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Bristol-Myers Squibb Company
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Regeneron Pharmaceuticals, Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Takeda Pharmaceutical Company Limited
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Antibody Production Market, By User
    • 6.1.1 Pharmaceutical & Biotechnology Companies
    • 6.1.2 Academic & Research Institutes
    • 6.1.3 Contract Research Organizations
  • 6.2 Antibody Production Market, By Technology
    • 6.2.1 Hybridoma Technology
    • 6.2.2 Phage Display Technology
    • 6.2.3 Transgenic Animals Technology
    • 6.2.4 Single-Cell Cloning Technology
    • 6.2.5 Recombinant DNA Technology
  • 6.3 Antibody Production Market, By Application
    • 6.3.1 Therapeutics
    • 6.3.2 Diagnostics
    • 6.3.3 Research
  • 6.4 Antibody Production Market, By Product Type
    • 6.4.1 Monoclonal Antibodies
    • 6.4.2 Polyclonal Antibodies
    • 6.4.3 Recombinant Antibodies
    • 6.4.4 Murine Antibodies
    • 6.4.5 Humanized Antibodies

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Antibody Production Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Antibody Production market is categorized based on

By Product Type

• Monoclonal Antibodies
• Polyclonal Antibodies
• Recombinant Antibodies
• Murine Antibodies
• Humanized Antibodies

By Application

• Therapeutics
• Diagnostics
• Research

By User

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Contract Research Organizations

By Technology

• Hybridoma Technology
• Phage Display Technology
• Transgenic Animals Technology
• Single-Cell Cloning Technology
• Recombinant DNA Technology

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Amgen Inc.
• Roche Holding AG
• AbbVie Inc.
• Johnson & Johnson
• Novartis AG
• Pfizer Inc.
• Merck & Co., Inc.
• Sanofi S.A.
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• GSK (GlaxoSmithKline plc)
• Regeneron Pharmaceuticals, Inc.
• Takeda Pharmaceutical Company Limited
• Biogen Inc.
• Genmab A/S